Spots Global Cancer Trial Database for Single Subject Neratinib in Bladder Cancer (NRR)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Single Subject Neratinib in Bladder Cancer (NRR)
Official Title: Single Subject Neratinib in Bladder Cancer
Study ID: NCT01956253
Conditions
Interventions
Study Description
Brief Summary: This study will be a single subject study to evaluate the efficacy of the HER2 kinase inhibitor, neratinib, in a patient with metastatic bladder cancer harboring a HER2-GRB7 gene fusion.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
North Carolina Cancer Hospital (UNC), Chapel Hill, North Carolina, United States
Contact Details
Name: William Kim, MD
Affiliation: UNC Lineberger Comprehensive Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
